OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer
Natalie I. Vokes, Kelsey Pan, Xiuning Le
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 24
Natalie I. Vokes, Kelsey Pan, Xiuning Le
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 24
Showing 24 citing articles:
Non–Small Cell Lung Cancer Metastatic Without Oncogenic Alterations
Nikolaj Frost, Martin Reck
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 6
Nikolaj Frost, Martin Reck
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 6
An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy
Saurav Verma, Daniel Breadner, Abhenil Mittal, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1302-1302
Open Access | Times Cited: 5
Saurav Verma, Daniel Breadner, Abhenil Mittal, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1302-1302
Open Access | Times Cited: 5
The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions
Angela Rina, Debora Maffeo, Francesca Minnai, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2882-2882
Open Access | Times Cited: 5
Angela Rina, Debora Maffeo, Francesca Minnai, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2882-2882
Open Access | Times Cited: 5
TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection
Ross A. Soo, Filippo de Marinis, Ji‐Youn Han, et al.
Clinical Lung Cancer (2023) Vol. 25, Iss. 1, pp. 80-84
Open Access | Times Cited: 11
Ross A. Soo, Filippo de Marinis, Ji‐Youn Han, et al.
Clinical Lung Cancer (2023) Vol. 25, Iss. 1, pp. 80-84
Open Access | Times Cited: 11
Analysis of ferritinophagy-related genes associated with the prognosis and regulatory mechanisms in non-small cell lung cancer
Hao Yuan, Xin Wang, Zhiyu Ni, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access
Hao Yuan, Xin Wang, Zhiyu Ni, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access
MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target
Gianluca Spitaleri, Pamela Trillo Aliaga, Ilaria Attili, et al.
Cancers (2023) Vol. 15, Iss. 19, pp. 4779-4779
Open Access | Times Cited: 10
Gianluca Spitaleri, Pamela Trillo Aliaga, Ilaria Attili, et al.
Cancers (2023) Vol. 15, Iss. 19, pp. 4779-4779
Open Access | Times Cited: 10
Tumor reduction after SARS‑CoV‑2 infection in a patient with lung cancer: A case report
Xiaoming Zhang, Jingyu Chen, Jie Sun, et al.
Oncology Letters (2024) Vol. 27, Iss. 4
Open Access | Times Cited: 3
Xiaoming Zhang, Jingyu Chen, Jie Sun, et al.
Oncology Letters (2024) Vol. 27, Iss. 4
Open Access | Times Cited: 3
LTBR acts as a novel immune checkpoint of tumor‐associated macrophages for cancer immunotherapy
Liang Wang, Jieyi Fan, Sifan Wu, et al.
iMeta (2024) Vol. 3, Iss. 5
Open Access | Times Cited: 3
Liang Wang, Jieyi Fan, Sifan Wu, et al.
iMeta (2024) Vol. 3, Iss. 5
Open Access | Times Cited: 3
Therapy for Stage IV Non–Small Cell Lung Cancer With and Without Driver Alterations: ASCO Living Guideline Clinical Insights
Dwight H. Owen, Ishmael Jaiyesimi, Natasha B. Leighl, et al.
JCO Oncology Practice (2024) Vol. 20, Iss. 7, pp. 893-898
Closed Access | Times Cited: 2
Dwight H. Owen, Ishmael Jaiyesimi, Natasha B. Leighl, et al.
JCO Oncology Practice (2024) Vol. 20, Iss. 7, pp. 893-898
Closed Access | Times Cited: 2
ADAM12 promotes the resistance of lung adenocarcinoma cells to EGFR-TKI and regulates the immune microenvironment by activating PI3K/Akt/mTOR and RAS signaling pathways
Keyu Li, Lingli Quan, Fang Huang, et al.
International Immunopharmacology (2023) Vol. 122, pp. 110580-110580
Closed Access | Times Cited: 6
Keyu Li, Lingli Quan, Fang Huang, et al.
International Immunopharmacology (2023) Vol. 122, pp. 110580-110580
Closed Access | Times Cited: 6
Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC
Edyta Maria Urbanska, Morten Grauslund, Peter R. Koffeldt, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13077-13077
Open Access | Times Cited: 6
Edyta Maria Urbanska, Morten Grauslund, Peter R. Koffeldt, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13077-13077
Open Access | Times Cited: 6
A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors
Fabrice Yves Ndjana Lessomo, Oscar Onayi Mandizadza, Chishimba Mukuka, et al.
European journal of medical research (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 5
Fabrice Yves Ndjana Lessomo, Oscar Onayi Mandizadza, Chishimba Mukuka, et al.
European journal of medical research (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 5
Next Generation Sequencing Analysis and its Benefit for Targeted Therapy of Lung Adenocarcinoma
Vlastimil Kulda, Jiří Polívka, Martin Svatoň, et al.
Cancer Genomics & Proteomics (2023) Vol. 20, Iss. 4, pp. 404-411
Open Access | Times Cited: 4
Vlastimil Kulda, Jiří Polívka, Martin Svatoň, et al.
Cancer Genomics & Proteomics (2023) Vol. 20, Iss. 4, pp. 404-411
Open Access | Times Cited: 4
Identifying the tumor-associated macrophage of lung adenocarcinoma reveals immune landscape through omics data integration
Xu Zhang, Liwei Wu, Xiaotian Zhang, et al.
Heliyon (2024) Vol. 10, Iss. 6, pp. e27586-e27586
Open Access | Times Cited: 1
Xu Zhang, Liwei Wu, Xiaotian Zhang, et al.
Heliyon (2024) Vol. 10, Iss. 6, pp. e27586-e27586
Open Access | Times Cited: 1
Perioperative Immuntherapie beim operablen Lungenkarzinom: aktuelle Studienlage und neue Therapiestandards
Uyen‐Thao Le, Birte Ohm, Severin Schmid
Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie (2024) Vol. 149, Iss. S 01, pp. S35-S44
Closed Access | Times Cited: 1
Uyen‐Thao Le, Birte Ohm, Severin Schmid
Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie (2024) Vol. 149, Iss. S 01, pp. S35-S44
Closed Access | Times Cited: 1
Harnessing p53 to Improve Immunotherapy for Lung Cancer Treatment
X. Niu, Luis A. Martinez
Cancer Research (2023) Vol. 84, Iss. 2, pp. 179-180
Closed Access | Times Cited: 3
X. Niu, Luis A. Martinez
Cancer Research (2023) Vol. 84, Iss. 2, pp. 179-180
Closed Access | Times Cited: 3
Nucleolar protein TAAP1/C22orf46confers pro-survival signaling in non-small cell lung cancer
Marietta Döring, Melanie Brux, Maciej Paszkowski‐Rogacz, et al.
Life Science Alliance (2024) Vol. 7, Iss. 4, pp. e202302257-e202302257
Open Access
Marietta Döring, Melanie Brux, Maciej Paszkowski‐Rogacz, et al.
Life Science Alliance (2024) Vol. 7, Iss. 4, pp. e202302257-e202302257
Open Access
The Association of Immune-Related Adverse Events with the Efficacy of Atezolizumab in Previously Treated Advanced Non-Small-Cell Lung Cancer Patients: A Single-Center Experience
Filip Marković, Mihailo Stjepanović, Natalija Samardžić, et al.
Cancers (2024) Vol. 16, Iss. 17, pp. 2995-2995
Open Access
Filip Marković, Mihailo Stjepanović, Natalija Samardžić, et al.
Cancers (2024) Vol. 16, Iss. 17, pp. 2995-2995
Open Access
Drug therapy for locally advanced and metastatic non-small cell lung cancer with MET mutation: indirect comparison
V. I. Ignatieva, S. К. Zyryanov, К. К. Лактионов, et al.
Medical Technologies Assessment and Choice (2024), Iss. 3, pp. 82-82
Open Access
V. I. Ignatieva, S. К. Zyryanov, К. К. Лактионов, et al.
Medical Technologies Assessment and Choice (2024), Iss. 3, pp. 82-82
Open Access
Significance of Ribonucleoside-diphosphate Reductase Subunit M2 in Lung Adenocarcinoma
Xiaojun Wang, Yun-Xia Huo, Pengjun Yang, et al.
Current Gene Therapy (2024) Vol. 25, Iss. 2, pp. 136-156
Closed Access
Xiaojun Wang, Yun-Xia Huo, Pengjun Yang, et al.
Current Gene Therapy (2024) Vol. 25, Iss. 2, pp. 136-156
Closed Access
THE ROLE OF PROGNOSTIC AND PREDICTIVE MARKERS IN TREATMENT OF NON-SMALL CELL LUNG CANCER
M. A. Krasavina, F.V. Moiseenko
Practical oncology (2024) Vol. 25, Iss. 2, pp. 145-153
Open Access
M. A. Krasavina, F.V. Moiseenko
Practical oncology (2024) Vol. 25, Iss. 2, pp. 145-153
Open Access
Efficacy of disitamab vedotin in non-small cell lung cancer with HER2 alterations: a multicenter, retrospective real-world study
Meiling Zhang, Li Wang, Qian Wang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Meiling Zhang, Li Wang, Qian Wang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Perioperative Immuntherapie beim operablen Lungenkarzinom: aktuelle Studienlage und neue Therapiestandards
Uyen‐Thao Le, Birte Ohm, Severin Schmid
TumorDiagnostik & Therapie (2024) Vol. 45, Iss. 09, pp. 604-613
Closed Access
Uyen‐Thao Le, Birte Ohm, Severin Schmid
TumorDiagnostik & Therapie (2024) Vol. 45, Iss. 09, pp. 604-613
Closed Access
Pembrolizumab with or without Concurrent Chemotherapy in Metastatic Non–Small-Cell Lung Cancer with High Programmed Death Ligand 1 Expression
D. Lui, E. Yu, MY Lim
Hong Kong Journal of Radiology (2024)
Open Access
D. Lui, E. Yu, MY Lim
Hong Kong Journal of Radiology (2024)
Open Access
